vs
Amphastar Pharmaceuticals, Inc.（AMPH）とPREFORMED LINE PRODUCTS CO（PLPC）の財務データ比較。上の社名をクリックして会社を切り替えられます
Amphastar Pharmaceuticals, Inc.の直近四半期売上が大きい（$183.1M vs $173.1M、PREFORMED LINE PRODUCTS COの約1.1倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs 4.9%、差は8.5%）。PREFORMED LINE PRODUCTS COの前年同期比売上増加率が高い（3.6% vs -1.8%）。Amphastar Pharmaceuticals, Inc.の直近四半期フリーキャッシュフローが多い（$24.6M vs $11.8M）。過去8四半期でPREFORMED LINE PRODUCTS COの売上複合成長率が高い（10.8% vs 3.2%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
プリフォームド・ライン・プロダクツ社（PLPC）は、送配電、通信、再生可能エネルギーインフラ分野向けのエンジニアリングハードウェアや部品を設計・製造・供給し、世界各国の事業者にネットワークの信頼性と業務効率を高めるソリューションを提供している。
AMPH vs PLPC — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $173.1M |
| 純利益 | $24.4M | $8.4M |
| 粗利率 | 46.8% | 29.8% |
| 営業利益率 | 19.4% | 6.8% |
| 純利益率 | 13.3% | 4.9% |
| 売上前年比 | -1.8% | 3.6% |
| 純利益前年比 | -35.7% | -19.3% |
| EPS（希薄化後） | $0.51 | $1.72 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $173.1M | ||
| Q3 25 | $191.8M | $178.1M | ||
| Q2 25 | $174.4M | $169.6M | ||
| Q1 25 | $170.5M | $148.5M | ||
| Q4 24 | $186.5M | $167.1M | ||
| Q3 24 | $191.2M | $147.0M | ||
| Q2 24 | $182.4M | $138.7M | ||
| Q1 24 | $171.8M | $140.9M |
| Q4 25 | $24.4M | $8.4M | ||
| Q3 25 | $17.4M | $2.6M | ||
| Q2 25 | $31.0M | $12.7M | ||
| Q1 25 | $25.3M | $11.5M | ||
| Q4 24 | $38.0M | $10.5M | ||
| Q3 24 | $40.4M | $7.7M | ||
| Q2 24 | $37.9M | $9.4M | ||
| Q1 24 | $43.2M | $9.6M |
| Q4 25 | 46.8% | 29.8% | ||
| Q3 25 | 51.4% | 29.7% | ||
| Q2 25 | 49.6% | 32.7% | ||
| Q1 25 | 50.0% | 32.8% | ||
| Q4 24 | 46.5% | 33.3% | ||
| Q3 24 | 53.3% | 31.1% | ||
| Q2 24 | 52.2% | 31.9% | ||
| Q1 24 | 52.4% | 31.3% |
| Q4 25 | 19.4% | 6.8% | ||
| Q3 25 | 13.2% | 7.4% | ||
| Q2 25 | 24.2% | 10.1% | ||
| Q1 25 | 21.9% | 8.8% | ||
| Q4 24 | 24.2% | 10.5% | ||
| Q3 24 | 29.8% | 7.1% | ||
| Q2 24 | 30.3% | 8.1% | ||
| Q1 24 | 27.9% | 8.2% |
| Q4 25 | 13.3% | 4.9% | ||
| Q3 25 | 9.0% | 1.5% | ||
| Q2 25 | 17.8% | 7.5% | ||
| Q1 25 | 14.8% | 7.8% | ||
| Q4 24 | 20.4% | 6.3% | ||
| Q3 24 | 21.1% | 5.2% | ||
| Q2 24 | 20.8% | 6.8% | ||
| Q1 24 | 25.1% | 6.8% |
| Q4 25 | $0.51 | $1.72 | ||
| Q3 25 | $0.37 | $0.53 | ||
| Q2 25 | $0.64 | $2.56 | ||
| Q1 25 | $0.51 | $2.33 | ||
| Q4 24 | $0.74 | $2.13 | ||
| Q3 24 | $0.78 | $1.54 | ||
| Q2 24 | $0.73 | $1.89 | ||
| Q1 24 | $0.81 | $1.94 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | — |
| 総負債低いほど良い | $608.7M | $38.3M |
| 株主資本純資産 | $788.8M | $475.5M |
| 総資産 | $1.6B | $653.6M |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | 0.08× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | — | ||
| Q3 25 | $276.2M | — | ||
| Q2 25 | $231.8M | — | ||
| Q1 25 | $236.9M | — | ||
| Q4 24 | $221.6M | — | ||
| Q3 24 | $250.5M | — | ||
| Q2 24 | $217.8M | — | ||
| Q1 24 | $289.6M | — |
| Q4 25 | $608.7M | $38.3M | ||
| Q3 25 | $608.6M | $36.0M | ||
| Q2 25 | $607.7M | $31.8M | ||
| Q1 25 | $603.9M | $29.1M | ||
| Q4 24 | $601.6M | $20.8M | ||
| Q3 24 | $596.4M | $27.2M | ||
| Q2 24 | $586.9M | $31.6M | ||
| Q1 24 | $594.0M | $55.0M |
| Q4 25 | $788.8M | $475.5M | ||
| Q3 25 | $776.7M | $466.3M | ||
| Q2 25 | $757.5M | $460.7M | ||
| Q1 25 | $751.3M | $435.8M | ||
| Q4 24 | $732.3M | $422.3M | ||
| Q3 24 | $727.7M | $429.0M | ||
| Q2 24 | $713.3M | $416.2M | ||
| Q1 24 | $672.4M | $413.4M |
| Q4 25 | $1.6B | $653.6M | ||
| Q3 25 | $1.7B | $644.6M | ||
| Q2 25 | $1.6B | $631.5M | ||
| Q1 25 | $1.6B | $592.5M | ||
| Q4 24 | $1.6B | $573.9M | ||
| Q3 24 | $1.5B | $592.0M | ||
| Q2 24 | $1.5B | $572.6M | ||
| Q1 24 | $1.6B | $586.1M |
| Q4 25 | 0.77× | 0.08× | ||
| Q3 25 | 0.78× | 0.08× | ||
| Q2 25 | 0.80× | 0.07× | ||
| Q1 25 | 0.80× | 0.07× | ||
| Q4 24 | 0.82× | 0.05× | ||
| Q3 24 | 0.82× | 0.06× | ||
| Q2 24 | 0.82× | 0.08× | ||
| Q1 24 | 0.88× | 0.13× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $21.9M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $11.8M |
| FCFマージンFCF / 売上 | 13.4% | 6.8% |
| 設備投資強度設備投資 / 売上 | 4.5% | 5.9% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | 2.60× |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $33.3M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $21.9M | ||
| Q3 25 | $52.6M | $18.9M | ||
| Q2 25 | $35.6M | $26.9M | ||
| Q1 25 | $35.1M | $5.7M | ||
| Q4 24 | $29.0M | $24.1M | ||
| Q3 24 | $60.0M | $9.4M | ||
| Q2 24 | $69.1M | $28.3M | ||
| Q1 24 | $55.3M | $5.8M |
| Q4 25 | $24.6M | $11.8M | ||
| Q3 25 | $47.2M | $8.3M | ||
| Q2 25 | $25.0M | $18.6M | ||
| Q1 25 | $24.4M | $-5.3M | ||
| Q4 24 | $16.6M | $20.6M | ||
| Q3 24 | $46.2M | $5.8M | ||
| Q2 24 | $63.1M | $24.6M | ||
| Q1 24 | $46.5M | $1.8M |
| Q4 25 | 13.4% | 6.8% | ||
| Q3 25 | 24.6% | 4.7% | ||
| Q2 25 | 14.3% | 10.9% | ||
| Q1 25 | 14.3% | -3.6% | ||
| Q4 24 | 8.9% | 12.3% | ||
| Q3 24 | 24.1% | 3.9% | ||
| Q2 24 | 34.6% | 17.7% | ||
| Q1 24 | 27.1% | 1.3% |
| Q4 25 | 4.5% | 5.9% | ||
| Q3 25 | 2.8% | 6.0% | ||
| Q2 25 | 6.1% | 4.9% | ||
| Q1 25 | 6.3% | 7.4% | ||
| Q4 24 | 6.7% | 2.1% | ||
| Q3 24 | 7.2% | 2.4% | ||
| Q2 24 | 3.3% | 2.7% | ||
| Q1 24 | 5.1% | 2.8% |
| Q4 25 | 1.35× | 2.60× | ||
| Q3 25 | 3.03× | 7.21× | ||
| Q2 25 | 1.15× | 2.12× | ||
| Q1 25 | 1.39× | 0.49× | ||
| Q4 24 | 0.76× | 2.30× | ||
| Q3 24 | 1.48× | 1.22× | ||
| Q2 24 | 1.82× | 3.02× | ||
| Q1 24 | 1.28× | 0.60× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
PLPC
セグメントデータなし
